cryoprecipitate vs prothrombin complex concentrate

Results: A total of 252 were included in the analysis [PCC+FFP:63; FFP:189]. 2019; 59:15601567. % Review both the approved and off-label indications for using prothrombin complex concentrate. Epub 2018 Jan 13. Human Plasma-derived Activated Prothrombin Complex Concentrate for Use in Patient with Inherited Hemophilia A or B and Inhibitors to Factor VIII or IX Feiba Recombinant Factor VIIa Concentrate for Use in Patients with Inherited Hemophilia A or B and Inhibitors to Factor VIII or IX NovoSeven RT SEVENFACT A novel coronavirus from patients with pneumonia in China, 2019. 2023. 20. It is now used to replace congenital or acquired vitamin-K deficiency warfarin-induced anticoagulant effect, particularly in the emergent setting. 2022 Nov 21;11(11):CD013551. There have been several randomized controlled trials of fibrinogen concentrate in cardiac surgical patients (Table 2).24,3542 One of the first trials conducted by Karlsson et al35 randomized elective coronary artery bypass grafting (CABG) patients who had a preoperative plasma fibrinogen concentration of 380 mg/L. 2017; 11:3339. trailer <> Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. 2022 Feb; [PubMed PMID: 34800389], Owen EJ,Gibson GA,Human T,Wolfe R, Thromboembolic Complications After Receipt of Prothrombin Complex Concentrate. 169 28 Fibrinogen concentrate was given based on the rotational thromboelastometry (ROTEM; TEM International, Munich, Germany) parameters.39 Fifteen minutes after fibrinogen concentrate was given, patients could receive prothrombin complex concentrate if ROTEM parameters remained abnormal. Karkouti K, von Heymann C, Jespersen CM, et al. 2018; 16:21502158. Patients with aortic stenosis have loss of large VWF multimers due to high shear stress, which is referred to as Heyde syndrome.50 The Heyde syndrome is similar to type 2a VWD, where there is a loss of VWF function and poor platelet adhesion to collagen. High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. 39 0 obj 2006; 4:14611469. FFP requires procurement from the blood bank and thawing before administration, factors that lead to delays in administration and anticoagulation reversal. Accessibility The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. 2011; 91:944982. We compared the standard dosage of FFP and PCC in terms of efficacy and safety for patients with mechanical heart valves undergoing interventional procedures while receiving Warfarin. 2013; 117:1422. 45. Dose of fibrinogen concentrate (mg) = Target plasma concentration (mg/dL) Measured plasma concentration (mg/dL)/1.7 body weight (kg). endobj Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. Cushing MM, Haas T. Fibrinogen concentrate for perioperative bleeding: what can we learn from the clinical trials? Instead, cryoprecipitate is used to treat acquired hypofibrinogenemia in cardiac surgery, multitrauma, obstetrical hemorrhage, and other critical care settings.12 Until recently, cryoprecipitate was the only effective treatment for acquired hypofibrinogenemia in cardiac surgical patients. 2007 Jan [PubMed PMID: 17174219], Franchini M,Lippi G, Prothrombin complex concentrates: an update. In this Pro-Con commentary article, we discuss the advantages and disadvantages of both products for treating acquired hypofibrinogenemia in the cardiac surgical patients. Cryoprecipitate contains factor VIII, von Willebrand factor (VWF), fibrinogen, factor XIII, and fibronectin. The association of prothrombin complex concentrates with - Springer Benson JW, Hraska V, Scott JP, Stuth EAE, Yan K, Zhang J, Niebler RA. Oncotarget. 15. 33 0 obj 61. Role of fibronectin assembly in platelet thrombus formation. Prothrombin Complex Concentrate - an overview | ScienceDirect Topics Prothrombin complex concentrates (PCCs) are a source of the vitamin K-dependent coagulation factors, including factors II, VII, IX and X and proteins C and S. They are isolated from the cryoprecipitate supernatant of large plasma pools after removal of antithrombin and factor XI. 18. 0000002270 00000 n 2017). 40 0 obj Safe in heart failure: PCC can be safely administered in patients with cardiac or renal impairment who may be unable totolerate large volumes of plasma. US Food and Drug Administration. Warfarin inhibits vitamin K-dependent synthesis of clotting factors II, VII, IX, and X and anticoagulant factors protein C and protein S. PCC contains factors II, IX, and X, and variable amounts of factor VII concentrate with a final overall clotting factor concentration approximately 25 times higher than in normal plasma. endobj Duvernay MT, Temple KJ, Maeng JG, et al. Research output: Contribution to journal Article peer . Adult cardiac surgery, Fresh Frozen Plasma (FFP), Cryoprecipitate, Prothrombin Complex Concentrate (PCCs) The . Two of these donations were not utilized. 40. Medizinische Klinik, Intensivmedizin und Notfallmedizin. 54. your express consent. 2018 Sep 24 [PubMed PMID: 30244638], Roman M,Biancari F,Ahmed AB,Agarwal S,Hadjinikolaou L,Al-Sarraf A,Tsang G,Oo AY,Field M,Santini F,Mariscalco G, Prothrombin complex concentrate in cardiac surgery: A systematic review and meta-analysis. Activation of PARs lead to the release of adenosine diphosphate (ADP) from dense granules and activation of the platelet surface glycoprotein IIb/IIIa receptor, which binds activated platelets to fibrinogen/fibrin.5,6, Clot strength is dependent on fibrinogen concentration, and multiple studies have shown that a fibrinogen concentration of >200 mg/dL is necessary for optimal hemostasis in cardiac surgical patients.3,7 The European guidelines recommend replacing fibrinogen when its concentration is <150 mg/dL in the noncardiac surgical patients.8 Clot firmness and plasma fibrinogen concentration predictably fall after cardiopulmonary bypass (CPB), mainly due to hemodilution and a lesser degree from consumption.2 Decreases in clotting factors of 30%50% are common after CPB and depend on CPB priming volume, retrograde autologous priming (RAP), autologous whole blood collection before CPB, and the amount of cell salvage.4,9. startxref Address correspondence to Nadia B. Hensley, MD, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, 1800 Orleans Ave, Zayed Tower 6212, Baltimore, MD 21287. In cases with long CPB duration, particularly in complex congenital heart surgery, acquired von Willebrand syndrome (VWS) is common, and cryoprecipitate may be a superior option for replacing both fibrinogen and large VWF multimers.51 Finally, patients on extracorporeal membrane oxygenation (ECMO) and patients with ventricular assist devices (VADs) are well known to have acquired VWS and may benefit from the treatment with cryoprecipitate compared to fibrinogen concentrate.5254. endobj If required the PCCs were administered in conjunction with fibrinogen concentrate, blood products (packed red cells, platelets, FFP, cryoprecipitate) and antifibrinolytic agents such as aprotinin or tranexamic acid. and transmitted securely. Disclaimer. This will be the first prospective randomized controlled clinical trial directly comparing Prothrombin Complex Concentrate (PCC) Compared to Fresh Frozen Plasma (FFP) for post cardiopulmonary bypass microvascular bleeding and factor-mediated coagulopathy. There are at least 4 randomized controlled studies of fibrinogen concentrate in the cardiac surgical patients who did not show benefits in terms of reduced RBC transfusion, reduced platelet transfusion, or reoperations for bleeding.38,4042 Three of these studies utilized fibrinogen concentrate after CPB, and 1 utilized fibrinogen concentrate before CPB. bleeding; cardiac surgery; critical care; safety. Blood products - Transfusion Guidelines Cryoprecipitate is derived from fresh frozen plasma (FFP), which is frozen within 8 hours of collection. The results demonstrate feasibility of utilizing the minimum amount of drug in order to achieve a desired effect. Rahe-Meyer N, Levy JH, Mazer CD, et al. Reprints will not be available from the authors. <> J Thromb Haemost. Pharmacotherapy. The patients in the rFVIIa group, required more cryoprecipitate than those in the 4-factor PCC group (4-factor PCC: 2 units (range 0-6) vs. rFVIIa: 2 units (range 0-8), p = 0.03). 2020; 56:1825. In vitro and observational studies have demonstrated the importance of fibrinogen replacement for adequate hemostasis, yet randomized controlled trials of fibrinogen treatment compared to placebo have not shown a mortality benefit.19 Cushing and Haas20 examined these clinical trials and determined that fibrinogens inconsistent efficacy may be related to design flaws in the trials themselves, including variable definitions for hypofibrinogenemia, inclusion of patients with insignificant bleeding, and off-protocol interventions. 2014; 113:922934. Epub 2017 Jul 12. Fibronectin is the least appreciated factor in cryoprecipitate and only recently has its role in hemostasis been elucidated. In: Journal of Trauma and Acute Care Surgery, Vol. Implications for reducing donor exposure. Acquired von Willebrand syndrome in congenital heart disease surgery: results from an observational case-series. 3. Recombinant activated factor VII is an excellent example of this phenomenon, where a clear pattern of increased thromboembolic risk was observed, as the drug was increasingly used off-label in the cardiac surgical patients.47,48. The largest randomized multicenter clinical trial of fibrinogen concentrate, the FIBrinogen REplenishment in Surgery (FIBRES) study, enrolled 725 patients at 11 centers in Canada (Table 2).24 This study included adult patients who had significant bleeding related to acquired hypofibrinogenemia after CPB, defined as fibrinogen <200 mg/dL by the Clauss method or the fibrin-based thromboelastometry test extrinsically activated with tissue factor and containing the platelet inhibitor cytochalasin D (FIBTEM) amplitude <10 mm at 10 minutes. Hoffman M, Jenner P. Variability in the fibrinogen and von Willebrand factor content of cryoprecipitate. 62. A Comparison of Prothrombin Complex Concentrate and Recombinant The total median dose requirement for 4-factor PCC was 1000 units (15 units/kg) and 2 mg (20 mcg/kg) for rFVIIa. [1]Processing techniques involving ion exchangers allow for the production of either three-factor (i.e., factors II, IX, and X) or four-factor (i.e., factors II, VII, IX, and X) PCC. The risk of pathogen transmission is one of the primary reasons that cryoprecipitate was removed from European markets. Okerberg CK, Williams LA III, Kilgore ML, et al. Cryoprecipitate therapy. Alternatively, fibrinogen concentrate has a known fibrinogen content, leading to predictable effects. Activated Prothrombin Complex - an overview | ScienceDirect Topics <> Adam EH, Meier J, Klee B, et al. endobj 2009; 108:751758. Even though allogeneic blood products have been screened since 1985 with nucleic acid testing for viruses such as hepatitis C and human immunodeficiency virus (HIV), it is impractical to screen for all viruses or emerging infectious diseases. Contributions of protease-activated receptors PAR1 and PAR4 to thrombin-induced GPIIbIIIa activation in human platelets. 14. 2018; 12:CD010649. Cappy et al30 reported that between January 20 and May 29 of 2020, 311 blood donations to the French National Blood Service were investigated including 268 postdonation infections (PDIs) and 43 trace-back donations (patients who reported COVID-19 symptoms within 14 days of donation). PCC dosing products are expressed as units of factor IX. Vincentelli A, Susen S, Le Tourneau T, et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult CSL Behring; Accessed November 27, 2020. The indications are listed below. 2021 Sep; [PubMed PMID: 34463792]. Acquired von Willebrand syndrome associated with left ventricular assist device. 42 0 obj basics of four-factor prothrombin complex concentrate . Heparin-induced thrombocytopenia (if the preparation contains heparin). Braz J Anesthesiol. In this document, the FDA describes the minimum factor VIII activity that is required for a single donor cryoprecipitate unit, which is 80 international units (IUs). 2007; 21:271289. J Thromb Haemost. Am J Clin Pathol. The following formula can be used to find the dose fibrinogen concentrate. 16. In conclusion, current evidence suggests that the risk of transmission of SARS-CoV-2 through the blood supply is exceedingly low. Today, the therapy for pharmacologically anticoagulated patients with ESLD presenting for liver . Srivastava A, Santagostino E, Dougall A, et al. Effects of hemodilution, blood loss, and consumption on hemostatic factor levels during cardiopulmonary bypass. During massive hemorrhage, thawing time may be detrimental, leading to an additional hemodilution or consumptive coagulopathy, as the minimal fibrinogen is given in other allogeneic blood products. US Food and Drug Administration (FDA) requirements for cryoprecipitate are outlined in the Code of Federal Regulations (CFR) Title 21, Section 640.5. Blood Transfus. The CFR further states that at least 4 cryoprecipitate units must be tested per month to determine the adequate factor VIII potency in any center that processes cryoprecipitate. JAMA Intern Med. World J Pediatr Congenit Heart Surg. Another advantage of fibrinogen concentrate is that it can be rapidly reconstituted and administered to patients. PCC contains significantly higher amounts of the clotting factors compared to FFP; one dose of PCC equals 8 to 16 units of FFP. Transfus Med Rev. Please enable scripts and reload this page. Epub 2016 May 11. J Heart Lung Transplant. FFP can be thawed in a water bath or a refrigerator, and plasma supernatant is separated from precipitate using centrifugation.13 Plasma supernatant is discarded except for a small volume (1015 mL), which is kept to suspend the cryoprecipitate.13 Multiple single donor units of cryoprecipitate (typically 5 or 6 units) are combined into a single pooled unit using sterile welding. Pooled cryoprecipitate is refrozen and stored at a temperature <18 C for 1 year. Crit Care. Callum J, Farkouh ME, Scales DC, et al. 1979; 241:17161717. Federal government websites often end in .gov or .mil. JAMA. Thromboembolic complicationslike pulmonary embolism, stroke, myocardial infarction, and deep venous thrombosis - today's PCCformulations differ vastly from those used in the 1980s and have a lower thrombosis risk. FFP versus Cryoprecipitate - UpToDate This extrapolates to ~1 thromboembolic event per 23,300 doses of 4 g of fibrinogen concentrate or an absolute risk of 0.004%. The approximate dosing required described below should achieve the normalization of INR (less than or equal to 1.2) within 1 hour of treatment. Conflicts of Interest: N. B. Hensley has served on the scientific advisory board for Octapharma USA (Paramus, NJ) and received royalties from Wolters Kluwer for uptodate.com contributions. Anesthesia & Analgesia. Ranucci M, Baryshnikova E, Crapelli GB, Rahe-Meyer N, Menicanti L, Frigiola A; Surgical Clinical Outcome REsearch (SCORE) Group. In particular, VWF and fibrinogen content can be affected by the amount of plasma that is left for suspension.15 Cryoprecipitate content is also affected by donor variability in factor activity and the type of freezer that is used for storage.16 Most single donor cryoprecipitate units contain at least 250 mg of fibrinogen, which translates to 1.25 g of fibrinogen for a 5 donor pool or 1.5 g of fibrinogen for a 6 donor pool.17 According to the American Red Cross, the mean factor VIII activity of a single donor cryoprecipitate unit is 136 IU and of a pool is 555 IU. When Heyde syndrome patients develop post-CPBacquired hypofibrinogenemia, they may be better served by the treatment with cryoprecipitate, which contains large VWF multimers. endobj Br J Anaesth. to maintaining your privacy and will not share your personal information without Circular of Information. / Khurrum, Muhammad; Ditillo, Michael; Obaid, Omar et al. 0000014668 00000 n J Am Heart Assoc. %%EOF endobj ; on behalf of the WFH Guidelines for the Management of Hemophilia. Fibrinogen concentrate has many potential advantages including a rapid administration, the predictability of dose response, and a lower risk for viral transmission, which aligns well with the FDAs recommendation to use pathogen-reduced blood products when feasible.62 However, fibrinogen concentrates lack of VWF, factor VIII, factor XIII, and fibronectin may reduce its hemostatic efficacy, particularly in cases with long CPB duration, in aortic stenosis patients, and in ECMO and left ventricular assist device (LVAD) patients. Vox Sang. 57. 2014; 54:109118. Crit Care. Currently, cryoprecipitate is rarely used to treat hemophilia A and VWD because concentrated, lyophilized, plasma-derived, and recombinant products are available for both diseases. 2020; 60(suppl 3):S17S23. Factor XIII, also known as fibrin stabilization factor, is contained in cryoprecipitate and its presence may add to cryoprecipitates superiority over fibrinogen concentrate in patients having complex cardiac surgery. endobj National Library of Medicine More recently, fibrinogen concentrate has been used off-label in the United States and is the standard in European countries and Canada to treat the acquired hypofibrinogenemia during cardiac surgery. Hensley, Nadia B. MD*; Mazzeffi, Michael A. MD, MPH, MSc, FASA, From the *Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. PCC contains significantly higher amounts of the clotting factors compared to FFP; one dose of PCC equals 8 to 16 units of FFP. Levy JH, Szlam F, Tanaka KA, Sniecienski RM. Rahe-Meyer N, Pichlmaier M, Haverich A, et al. H|T]o6}# IeO[niQ@Fm htZo%y9bCOkBJjTk0F`DCBZaF mh-lrcVjtte~tvZ8oBo)LvKlqb?/?oB]VRk #|3ldcyW/XS?ij3br0a7ZRle It was developed as a treatment for haemophilia but this use has now been replaced by Factor VIII concentrate. Methods In anaesthetized mildly hypothermic pigs, 65-70% of total blood volume was substituted in phases with hydroxyethyl starch and red cells. Koch C, Li L, Figueroa P, Mihaljevic T, Svensson L, Blackstone EH. Unauthorized use of these marks is strictly prohibited. Listen to this Article of the Month podcast and more from OpenAnesthesia.org by visiting http://journals.lww.com/anesthesia-analgesia/pages/default.aspx. 2016 Jul;91(7):705-8. doi: 10.1002/ajh.24384. Prothrombin complex concentrate offers several advantages over FFP, most importantly, the small volume needed to reverse anticoagulation. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. 29. Single-dose glass vial of Prothrombinex-VF with a rubber stopper closed with an aluminium seal One glass vial of 20 mL water for injection One Mix2Vial TM filter transfer set Contents: 500 IU of Factor IX ~500 IU of Factor II ~500 IU of Factor X Excipients: Human plasma proteins <500 mg Antithrombin III 25 IU Heparin Sodium 192 IU Sodium 112 mg HHS Vulnerability Disclosure, Help PCC is leukocyte-free and less likely to cause infusion reactions. Transfusion. 24. 41 0 obj Given the increased emphasis that has been placed on reducing allogeneic transfusion in the cardiac surgical patients, the advantages and disadvantages of using fibrinogen concentrate or cryoprecipitate to treat acquired hypofibrinogenemia in the cardiac surgical patients must be considered. Bilecen et al42 randomized patients (n = 120) having complex cardiac surgery (CABG + valve, multivalve, aortic root, ascending aorta, or arch repair) to receive fibrinogen concentrate or placebo if there was post-CPB bleeding >60 mL after attempts at surgical hemostasis. In the Randomized Evaluation of Fibrinogen Versus Placebo in Complex Cardiovascular Surgery (REPLACE) trial, 152 patients undergoing elective aortic replacement surgery were randomized to receive either fibrinogen concentrate or placebo, depending on whether there was a bleeding mass of 60250 g on surgical packing post-CPB. PCC exists in two varieties: 3-factor PCC and 4-factor PCC. Nonetheless, viral inactivation of fibrinogen concentrate further reduces any risk of transmitting SARS-CoV-2. Prothrombincomplex concentrates (PCCs) are highly purified concentrates with haemostatic activity pre- paredfrom pooled plasma. 0000000856 00000 n 8600 Rockville Pike endobj 49 0 obj 13. Association of off-label drug use and adverse drug events in an adult population. The FDA-approved indication is for urgent reversal of acquired coagulation factor deficiency induced by warfarin-induced anticoagulation in patients presenting with major acute bleeding (intracerebral hemorrhage-ICH) or needing urgent invasive surgery or procedure. 48 0 obj There was 1 vein graft occlusion in the fibrinogen concentrate group, and no vein graft occlusions in the control group. 0000005449 00000 n Patients were included if they were at least 18 years of age and had undergone cardiac surgery with bleeding requiring intervention with 4-factor PCC or rFVIIa. Abbreviations: AVR, aortic valve replacement; CABG, coronary artery bypass grafting; CI, confidence interval; CPB, cardiopulmonary bypass; cryo, cryoprecipitate; CT, computed tomography; FC, fibrinogen concentrate; FFP, fresh frozen plasma; FIBTEM, fibrin-based thromboelastometry test extrinsically activated with tissue factor and containing the platelet inhibitor cytochalasin D; IQR, interquartile range; LIMA, left internal mammary artery; MCF, maximum clot firmness; OR, odds ratio; postop, postoperative; prox, proximal; RBC, red blood cell; TAA, thoracic aortic aneurysm; TAAA, thoracoabdominal aneurysm. 2017. Whether to use fibrinogen concentrate or cryoprecipitate as a first-line therapy for the treatment of acquired hypofibrinogenemia in the cardiac surgical patients continues to be a subject of intense debate in the United States. 2011; 158:820825.e1. Recommendations | Blood transfusion | Guidance | NICE Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. xref Comparison between Prothrombin Complex Concentrate (PCC) and Fresh Solomon et als43 pharmacovigilance evaluation of fibrinogen concentrate over a 27-year period specifically analyzed the risk of thromboembolism. Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, Maryland. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study. Frontiers | Prothrombin Complex Concentrate in Liver Transplant Surgery Fibrinogen concentrates higher cost and lack of regulatory approval for treating acquired hypofibrinogenemia continue to be significant impediments to more widespread use in the United States despite widespread use in Canada and Europe. JAMA. 2005; 19:459467. <> 91, No. 2016 Nov [PubMed PMID: 27726162], Kopko PM,Bux J,Toy P, Antibodies associated with TRALI: differences in clinical relevance. 2023 May;14(3):282-288. doi: 10.1177/21501351231162911. It is now usedas replacement therapy forcongenital or acquired vitamin-K deficiency warfarin-induced anticoagulant effect, particularly in the emergent setting. 2018; 127:612621. 0000001394 00000 n Efficacy of fibrinogen concentrate in major abdominal surgerya prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei. Prothrombin complex concentrates (PCCs) are a source of the vitamin K-dependent coagulation factors, including factors II, VII, IX and X and proteins C and S. They are isolated from the cryoprecipitate supernatant of large plasma pools after removal of antithrombin and factor XI. Prothrombin complex concentrate versus fresh-frozen plasma for - PubMed You may be trying to access this site from a secured browser on the server. [1] [3] It may also be used for reversal of warfarin therapy. Each vial has about 500 units of factor IX. 2018; 37:985991. Crit Care. J Clin Invest. Updated information for blood establishments regarding the COVID-19 pandemic and blood donation. The authors found that 67.2% of patients in the treatment arm avoided any allogeneic transfusion (primary outcome) compared to 44.8% in the control group (odds ratio [OR], 0.40; 95% confidence interval [CI], 0.19-0.84). Sniecinski RM, Chandler WL. Bleeding/perioperative Prophylaxis of Bleeding During Vitamin K Antagonist Therapy, INR: 2 to less than 4: 25 units/kg; maximum dose: 2500 units, INR: 4 to 6: 35 units/kg; maximum dose: 3500 units, INR: greater than 6: 50 units/kg; maximum dose: 5000 units. The treatment with fibrinogen concentrate will not replace VWF multimers, and poor platelet adhesion may persist despite normalization of fibrinogen. In 1 group (n = 5), patients were treated with a transfusion algorithm based on the platelet count at cross-clamp removal and bleeding (defined by >60 g of blood weighed on surgical swabs), and in the other group (n = 10), patients were given fibrinogen concentrate before being transfused according to an algorithm. endstream endobj 170 0 obj <>>> endobj 171 0 obj <. Name: Michael A. Mazzeffi, MD, MPH, MSc, FASA. . Anesth Analg. Fibrinogen concentrate has several potential advantages over cryoprecipitate, but there are also potential disadvantages. <> <> 38 0 obj Mol Pharmacol.

Ibew 72 Job Calls, Mta Employee Salaries By Name, Articles C